XOMA — XOMA Royalty Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 791908 ·
Last close
$41.79
Market Cap
$738.79M
52W High
$42.81
52W Low
$25.72
ADV30
127,490
Next earnings
2026-05-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 310,000 | — | -480,000 | 4,465,000 | 271,858,000 | 85,600,000 | 158,963,000 |
| Dec 2025 | 1,432,000 | — | 2,182,000 | 6,103,000 | 272,698,000 | 82,908,000 | 188,757,000 |
| Sep 2025 | 532,000 | — | -1,330,000 | 14,051,000 | 263,151,000 | 45,189,000 | 155,194,000 |
| Jun 2025 | 5,379,000 | — | 4,603,000 | 9,191,000 | 223,456,000 | 75,060,000 | 131,002,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$6,794,000
Investing CF
$64,131,000
Financing CF
$-27,209,000
CapEx
$-114,000
Dividends Paid
$-5,528,000
Buybacks
$-16,434,000
EPS Diluted TTM
$1.57
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,217,249,000
Inventory
—
Receivables
$23,319,000
ST Investments
$494,000
EBIT TTM
$46,837,000
Pretax Income TTM
$33,914,000
Interest Exp TTM
$12,923,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$48,555,000
EBITDA
$8,295,000
Free Cash Flow
$-13,069,500
Enterprise Value
$582,795,648
Total Cash
$86,094,000
Total Debt
$124,732,000
Shares Out
17,678,742
Trailing EPS
$1.57
Book Value
$7.07
ROE
34.2%
ROA
1.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,660,000 | 11,384,000 | 31,712,000 | 272,698,000 | 188,757,000 | — | 2,871,000 |
| Dec 2024 | 10,220,000 | -39,976,000 | -13,821,000 | 221,277,000 | 159,375,000 | — | -13,748,000 |
| Dec 2023 | 4,758,000 | -23,463,000 | -40,831,000 | 234,301,000 | 145,580,000 | — | -18,158,000 |
| Dec 2022 | 6,027,000 | -17,414,000 | -17,104,000 | 140,382,000 | 16,368,000 | — | -12,879,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.14
Max Pain — expiry 2026-09-18
max pain strike: $45.00 · spot: $41.95 · call oi: 856 · put oi: 3,842
Expected Move to 2026-09-18:
±$4.03
(9.59%) —
implied range
$37.93 –
$45.98
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GERN | GERON CORP | $737.75M | $1.15 | — |
| CYRX | Cryoport, Inc. | $736.88M | $14.62 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $734.58M | $4.98 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $747.81M | $12.65 | — |
| ANRO | Alto Neuroscience, Inc. | $753.47M | $21.47 | — |
News headlines (Yahoo Finance, 1h cache)
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
2026-06-12 20:05 · Yahoo
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
2026-05-15 21:25 · Yahoo
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 22:05 · Yahoo
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
2026-05-08 13:35 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-06 22:30 · Yahoo
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
2026-04-28 09:53 · Yahoo
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
2026-04-27 20:11 · Yahoo
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
2026-04-27 11:00 · Yahoo
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
2026-03-26 10:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.